Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Axsome Therapeutics, Inc.AXSM · Entity 2469 | Director | June 08, 2026 | June 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Axsome Therapeutics, Inc.
Report date June 08, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 30,389 |
Ending reported balance
After 2026-06-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-08 · Exercise / conversion · Acquired 1,429 · Balance 31,032 F2: On June 6, 2025, the Reporting Person was granted 1,429 RSUs, all of which vested upon the one-year anniversary of the date of grant. F1: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. Row 2 · 2026-06-10 · Sale · Disposed 643 · Balance 30,389 F3: Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed. F4: These shares were sold to cover taxes associated with the settlement of RSUs that were initially granted to the Reporting Person on June 6, 2025. F5: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $245.17 and $253.04. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-08 · Exercise / conversion · Disposed 1,429 · Balance 0 F1: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 403,856 |
Reported balance
Holding disclosure · report date 2026-06-08 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 403,856 F6: Such shares are held by an entity, of which the reporting person has voting and dispositive power, and therefore, the reporting person is deemed to be the indirect beneficial owner of such shares. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
F2: On June 6, 2025, the Reporting Person was granted 1,429 RSUs, all of which vested upon the one-year anniversary of the date of grant.
F3: Such transaction was pursuant to a pre-approved 10b5-1 plan, which has now been completed.
F4: These shares were sold to cover taxes associated with the settlement of RSUs that were initially granted to the Reporting Person on June 6, 2025.
F5: Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $245.17 and $253.04.
F6: Such shares are held by an entity, of which the reporting person has voting and dispositive power, and therefore, the reporting person is deemed to be the indirect beneficial owner of such shares.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 17, 2020 Filed Mar 20, 2020 01:17 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantStock Option (Right to Buy) · Derivative | 3,308 | $0.00 Strike: $45.14 | $0.00 |
DisclosureSEC source: 0001179110-20-004007 · edgar.xml · derivative · entry 1 Coleman Mark · CIK 0001658379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,308 Underlying: Common Stock · 3,308 shares Expires 2030-03-16 F1 · shares: Represents 3,308 options elected to be received in lieu of cash compensation earned in 2019. All of such options are immediately exercisable. Read SEC document |
| June 26, 2019 Filed Jun 27, 2019 11:18 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | PurchaseCommon Stock | 15,800 | $23.10 | $364,980.00 |
DisclosureSEC source: 0001179110-19-008149 · edgar.xml · nonDerivative · entry 2 Coleman Mark · CIK 0001658379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 668,848 F2 · price: The price reported in Column 4 is an average price. These shares were purchased by the reporting person in multiple transactions at prices ranging from $22.90 to $23.25, inclusive. The reporting person undertakes to provide to Axsome Therapeutics, Inc., the staff of the Securities and Exchange Commission, and others pursuant to applicable securities laws, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| June 25, 2019 Filed Jun 27, 2019 11:18 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | PurchaseCommon Stock | 400 | $23.25 | $9,300.00 |
DisclosureSEC source: 0001179110-19-008149 · edgar.xml · nonDerivative · entry 1 Coleman Mark · CIK 0001658379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 653,048 F1 · price: The price reported in Column 4 is an average price. These shares were purchased by the reporting person in multiple transactions at prices ranging from $23.24 to $23.25, inclusive. The reporting person undertakes to provide to Axsome Therapeutics, Inc., the staff of the Securities and Exchange Commission, and others pursuant to applicable securities laws, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| June 07, 2019 Filed Jun 10, 2019 22:20 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantStock Option (Right to Buy) · Derivative | 13,000 | $0.00 Strike: $22.03 | $0.00 |
DisclosureSEC source: 0001104659-19-034641 · a4.xml · derivative · entry 1 Coleman Mark · CIK 0001658379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2029-06-07 F1 · derivative.exercise_date: The option vests in full on the one-year anniversary of the date of grant, June 7, 2020. Read SEC document |
| May 13, 2019 Filed May 15, 2019 11:21 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | PurchaseCommon Stock | 4,650 | $21.44 | $99,696.00 |
DisclosureSEC source: 0001179110-19-006055 · edgar.xml · nonDerivative · entry 1 Coleman Mark · CIK 0001658379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 652,648 F1 · price: The price reported in Column 4 is an average price. These shares were purchased by the reporting person in multiple transactions at prices ranging from $21.42 to $21.49, inclusive. The reporting person undertakes to provide to Axsome Therapeutics, Inc., the staff of the Securities and Exchange Commission, and others pursuant to applicable securities laws, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| March 19, 2019 Filed Mar 21, 2019 20:06 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantStock Option (Right to Buy) · Derivative | 25,652 | $0.00 Strike: $12.95 | $0.00 |
DisclosureSEC source: 0001104659-19-016569 · a4.xml · derivative · entry 1 Coleman Mark · CIK 0001658379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,652 Underlying: Common Stock · 25,652 shares Expires 2029-03-18 F1 · shares: Represents 25,652 options elected to be received in lieu of cash compensation earned in 2018. All of such options are immediately exercisable. Read SEC document |
| March 19, 2019 Filed Mar 21, 2019 11:05 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | PurchaseCommon Stock | 5,100 | $12.18 | $62,118.00 |
DisclosureSEC source: 0001104659-19-016423 · a4.xml · nonDerivative · entry 1 Coleman Mark · CIK 0001658379 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 5,100 F1 · price: The price reported in Column 4 is an average price. These shares were purchased by the reporting person in multiple transactions at prices ranging from $12.09 to $12.53, inclusive. The reporting person undertakes to provide to Axsome Therapeutics, Inc., the staff of the Securities and Exchange Commission, and others pursuant to applicable securities laws, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnote (1) to this Form 4. F2 · ownership.nature: Such shares were purchased by an entity, of which the reporting person has voting and dispositive power, and therefore, the reporting person is deemed to be the indirect beneficial owner of such shares. Read SEC document |
| June 01, 2018 Filed Jun 6, 2018 00:21 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantStock Options (right to buy) · Derivative | 13,000 | $0.00 Strike: $3.45 | $0.00 |
DisclosureSEC source: 0001104659-18-038401 · a4.xml · derivative · entry 1 Coleman Mark · CIK 0001658379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2028-06-01 F1 · derivative.exercise_date: The option vests in full on the one-year anniversary of the date of grant, June 1, 2019. Read SEC document |
| March 12, 2018 Filed Apr 5, 2018 14:05 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantStock Option (Right to Buy) · Derivative | 27,297 | $0.00 Strike: $2.85 | $0.00 |
DisclosureSEC source: 0001104659-18-022602 · a4.xml · derivative · entry 1 Coleman Mark · CIK 0001658379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,297 Underlying: Common Stock · 27,297 shares Expires 2028-03-11 F1 · shares: Represents 27,297 options elected to be received in lieu of cash compensation earned in 2017. All of such options are immediately exercisable. Read SEC document |
| March 15, 2017 Filed Mar 17, 2017 20:55 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantStock Option (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $4.95 | $0.00 |
DisclosureSEC source: 0001104659-17-017637 · a4.xml · derivative · entry 2 Coleman Mark · CIK 0001658379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2027-03-14 F2 · derivative.exercise_date: The option vests in full on the one-year anniversary of the date of grant, March 15, 2018. Read SEC document |
| March 15, 2017 Filed Mar 17, 2017 20:55 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantStock Option (Right to Buy) · Derivative | 26,456 | $0.00 Strike: $4.95 | $0.00 |
DisclosureSEC source: 0001104659-17-017637 · a4.xml · derivative · entry 1 Coleman Mark · CIK 0001658379 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,456 Underlying: Common Stock · 26,456 shares Expires 2027-03-14 F1 · shares: Represents 11,000 options granted as compensation for service during 2016 and 15,456 options elected to be received in lieu of cash compensation earned in 2016. All of such options are immediately exercisable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.